Guilford Pharmaceuticals, Inc.

US Government As Represented by the Secretary of the Army

Neuren Pharmaceuticals Limited

Xi-Chun May Lu

Barbara S Slusher

Frank Casper Tortella

Krystyna Wozniak

Peter David Gluckman

Margaret Anne Brimble

Mark W Brown

Larry R Holmes, Jr

Jitendra Ramanlal Dave

Zachary J Larimore

Mark F Arnold

Deborah A Shear

Kara E Schmid

Lai Yee Leung

Anthony Joseph Williams

Douglas Wilson

Zhiyong Chen

Jed A Hartings

Zhilin Liao

Divina Gryder

Jay E Bartlett

Mark P Easterday

Andrea Mountney

An apparatus and method for inflicting brain injury on a laboratory animal that employs a platform for supporting the laboratory animal. The platform defines an opening for positioning the head of the laboratory animal over the opening. A projectile is launched from a projectile launching device orientated below the opening of the platform. The projectile launching device has a means for propelling the projectile directly at and/or through the opening of said platform, thereby inflicting brain injury on the animal via either a pressure wave or concussive impact of the projectile. Without helmet, direct impact of the projectile results in severe traumatic brain injury. Use of helmet protects animals from skull fracture, subdural hematoma, intracerebral hemorrhage and contusion yet produces mild concussion-like pathology.

Device and method for inducing brain injury in animal test subjects

Aspects of this invention include the use of G-2MePE to treat patients with brain injury characterized by non-convulsive seizures. G-2MePE is useful in treating brain injuries caused by traumatic brain injury, stroke, hypoxia/ischemia and toxic injury.

Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate

The present invention relates to methods for regulating the release of TGF-&bgr; from living cells in vitro or in vivo, comprising bringing the cells into contact with an effective amount of a NAALADase inhibitor. Such methods are believed to be useful for affecting neuroregeneration, cell proliferation, cell differentiation, extracellular matrix formation, myelination, inflammation, immune function, liver function, pancreatic function, angiogenesis, or wound healing; and/or for preventing or treating diabetes.

Methods for treating certain diseases using naaladase inhibitors

The present invention relates to methods of using NAALADase inhibitors to regulate TGF-&bgr; and to treat neurodegenerative disorders, extracellular matrix formation disorders, cell-growth related diseases, infectious diseases, immune related diseases, epithelial tissue scarring, collagen vascular diseases, fibroproliferative disorders, connective tissue disorders, inflammatory diseases, respiratory distress syndrome and infertility.

Growing community of inventors

Laurel, MD, United States of America

Xi-Chun May Lu